MARKET

JAZZ

JAZZ

Jazz Phrmt
NASDAQ

Real-time Quotes | Nasdaq Last Sale

148.42
+0.70
+0.47%
Closed 16:13 10/20 EDT
OPEN
148.69
PREV CLOSE
147.72
HIGH
150.41
LOW
147.91
VOLUME
461.15K
TURNOVER
--
52 WEEK HIGH
156.27
52 WEEK LOW
86.88
MARKET CAP
8.23B
P/E (TTM)
64.33
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
IPO Update: NLS Pharmaceutics Readies $20 Million IPO Plan
NLS Pharmaceutics has filed to raise $20 million in a U.S. IPO.The firm is advancing treatments for narcolepsy and ADHD.NLSP is thinly capitalized and has made no apparent progress on beginning trials for its lead candidate, so I'll pass on the IPO.
Seekingalpha · 12h ago
Jazz Announces Topline Data, And Other News: The Good, Bad And Ugly Of Biopharma
Jazz Pharmaceuticals announces topline data from Phase 3 Xywav trial.MacroGenics reports positive data for flotetuzumab immunotherapy.Merck provides updated positive data for Keytruda in lung cancer.
Seekingalpha · 17h ago
Jazz Pharma's Xywav late-stage study results published in peer reviewed journal
Jazz Pharmaceuticals (JAZZ) has announced the publication of Phase 3 study results of Xywav (calcium, magnesium, potassium and sodium oxybates) oral solution, for the treatment of cataplexy or excessive daytime
Seekingalpha · 22h ago
Jazz Pharma Reports Results Of Phase 3 Xywav Trial For Cataplexy, Excessive Daytime Sleepiness In Patients With Narcolepsy Published In SLEEP; Showed 'highly statistically significant differences in median change...' vs Placebo
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the publication of the global Phase 3 double-blind, placebo-controlled, randomized-withdrawal, multicenter study of Xywav™ (calcium, magnesium, potassium and
Benzinga · 22h ago
Jazz Pharmaceuticals Announces SLEEP Publication of Phase 3 Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Study in Cataplexy or Excessive Daytime Sleepiness in Patients with Narcolepsy
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the publication of the global Phase 3 double-blind, placebo-controlled, randomized-withdrawal, multicenter study of Xywav™ (calcium, magnesium, potassium and sodium oxybates) oral solution, for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. The results were published in SLEEP, the peer-reviewed, international journal of the Sleep Research Society.
PR Newswire · 22h ago
Jazz Pharmaceuticals Announces Webcast for Xywav Investor Update
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Monday, October 26, 2020 at 4:30 p.m. EDT / 8:30 p.m. GMT to provide investors with an update on Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, which was approved by the U.S. Food and Drug Administration on July 21, 2020 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. The company expects Xywav to be commercially available in early November.
PR Newswire · 1d ago
Jazz Pharmaceuticals to Report 2020 Third Quarter Financial Results on November 2, 2020
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 third quarter financial results on Monday, November 2, 2020, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST/9:30 p.m. GMT to discuss third quarter 2020 financial results and provide a business and financial update.
PR Newswire · 1d ago
Jazz Pharma investor event October 26 on Xywav launch
Jazz Pharmaceuticals (JAZZ) will host a virtual investor event on Monday, October 26, at 4:30 pm ET to discuss the commercial launch of Xywav (calcium, magnesium, potassium, and sodium oxybates)
Seekingalpha · 1d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of JAZZ. Analyze the recent business situations of Jazz Phrmt through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average JAZZ stock price target is 171.61 with a high estimate of 205.00 and a low estimate of 117.00.
EPS
Institutional Holdings
Institutions: 605
Institutional Holdings: 57.63M
% Owned: 103.91%
Shares Outstanding: 55.46M
TypeInstitutionsShares
Increased
136
4.55M
New
113
1.55M
Decreased
142
3.85M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.02%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Chairman/Chief Executive Officer/Director
Bruce Cozadd
President/Chief Operating Officer
Daniel Swisher
Chief Financial Officer/Executive Vice President
Renee Gala
Executive Vice President/General Manager
Kimberly Sablich
Executive Vice President
Robert Iannone
Senior Vice President/General Counsel
Neena Patil
Senior Vice President
Finbar Larkin
Senior Vice President
Samantha Pearce
Chief Accounting Officer/Vice President
Patricia Carr
Independent Director
Paul Berns
Independent Director
Patrick Enright
Independent Director
Peter Gray
Independent Director
Heather McSharry
Independent Director
Seamus Mulligan
Independent Director
Kenneth O'Keefe
Independent Director
Anne O'Riordan
Independent Director
Norbert Riedel
Independent Director
Elmar Schnee
Independent Director
Catherine Sohn
Independent Director
Rick Winningham
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About JAZZ
Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Jazz Pharmaceuticals PLC stock information, including NASDAQ:JAZZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAZZ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading JAZZ stock methods without spending real money on the virtual paper trading platform.